HIV serostatus disclosure in the treatment cascade: evidence from Northern Tanzania.

Jan Ostermann, Brian Pence, Kathryn Whetten, Jia Yao, Dafrosa Itemba, Venance Maro, Elizabeth Reddy, Nathan Thielman
Author Information
  1. Jan Ostermann: a Duke Global Health Institute , Duke University , Durham , NC , USA.
  2. Brian Pence: b Center for Health Policy and Inequalities Research , Duke University , Durham , NC , USA.
  3. Kathryn Whetten: a Duke Global Health Institute , Duke University , Durham , NC , USA.
  4. Jia Yao: b Center for Health Policy and Inequalities Research , Duke University , Durham , NC , USA.
  5. Dafrosa Itemba: g Tanzania Women Research Foundation , Moshi , Tanzania.
  6. Venance Maro: h Kilimanjaro Christian Medical Center , Moshi , Tanzania.
  7. Elizabeth Reddy: i Upstate Medical University , Syracuse , NY , USA.
  8. Nathan Thielman: a Duke Global Health Institute , Duke University , Durham , NC , USA.

Abstract

HIV serostatus disclosure plays an important role in HIV transmission risk reduction and is positively associated with HIV medication adherence and treatment outcomes. However, to date, no study has quantified the role of disclosure across the HIV treatment cascade, particularly in Sub-Saharan Africa. We used data from a cohort of HIV-infected adults in Northern Tanzania to describe associations between disclosure and engagement and retention in the HIV treatment cascade. Between 2008 and 2009, the Coping with HIV/AIDS in Tanzania (CHAT) study enrolled 260 clients newly diagnosed with HIV and 492 HIV-infected patients in established HIV care in two large HIV care and treatment centers in Northern Tanzania. Participants aged 18 and older completed annual clinical assessments and twice-annual in-person interviews for 3.5 years. Using logistic regression models, we assessed sociodemographic correlates of HIV serostatus disclosure to at least one household member, and associations between this disclosure measure and linkage to care, evaluation for antiretroviral therapy (ART) eligibility, ART coverage, and rates of undetectable HIV RNA levels during the follow-up period. Married individuals and those diagnosed earlier were more likely to have disclosed their HIV infection to at least one household member. During follow-up, HIV serostatus disclosure was associated with higher rates of linkage to care, evaluation for ART eligibility, and ART coverage. No significant association was observed with rates of undetectable viral loads. Marginal effects estimates suggest that a 10 percentage-point lower probability of linkage to care for those who did not disclose their HIV serostatus (86% vs. 96%; p = 0.035) was compounded by an 18 percentage-point lower probability of ever receiving a CD4 count (62% vs. 80%; p = .039), and a 20 percentage-point lower probability of ever receiving ART (55% vs. 75%; p = .029). If causal, these findings suggest an important role for disclosure assistance efforts across the HIV treatment cascade.

Keywords

References

  1. AIDS Care. 2009 Feb;21(2):197-206 [PMID: 19229689]
  2. AIDS Care. 2013;25(3):326-36 [PMID: 22866903]
  3. AIDS. 2012 Oct 23;26(16):2059-67 [PMID: 22781227]
  4. PLoS One. 2014;9(5):e95469 [PMID: 24798428]
  5. Clin Infect Dis. 2014 Apr;58(7):1012-4 [PMID: 24429442]
  6. PLoS One. 2012;7(5):e36304 [PMID: 22606252]
  7. J Int AIDS Soc. 2010;13:37 [PMID: 20863399]
  8. Clin Infect Dis. 2007 Dec 1;45(11):1492-8 [PMID: 17990233]
  9. AIDS Behav. 2013 Sep;17(7):2528-39 [PMID: 23474643]
  10. BMC Public Health. 2014;14:1154 [PMID: 25377362]
  11. Curr HIV/AIDS Rep. 2014 Dec;11(4):376-92 [PMID: 25323298]
  12. PLoS One. 2015;10(5):e0126026 [PMID: 25946065]
  13. Soc Sci Med. 2014 May;108:166-74 [PMID: 24641881]
  14. AIDS Care. 2011 Feb;23(2):129-38 [PMID: 20645192]
  15. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e104-9 [PMID: 24525471]
  16. AIDS Care. 2014;26(11):1352-8 [PMID: 24517083]
  17. PLoS One. 2014;9(11):e111421 [PMID: 25372479]
  18. J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19666 [PMID: 25397416]
  19. Bull World Health Organ. 2004 Apr;82(4):299-307 [PMID: 15259260]
  20. AIDS. 2015 Jun;29 Suppl 1:S7-S23 [PMID: 26049541]

Grants

  1. P30 AI064518/NIAID NIH HHS
  2. R01 MH078756/NIMH NIH HHS
  3. 5P30 AI064518/NIAID NIH HHS
  4. 5R01MH078756/NIMH NIH HHS

MeSH Term

Adult
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Cohort Studies
Female
HIV Infections
Humans
Logistic Models
Male
Medication Adherence
Tanzania
Truth Disclosure
Young Adult

Word Cloud

Created with Highcharts 10.0.0HIVdisclosuretreatmentcareARTserostatuscascadeTanzanialinkageroleNorthernratespercentage-pointlowerprobabilityvsimportantassociatedstudyacrossSub-SaharanAfricaHIV-infectedassociationsdiagnosed18leastonehouseholdmemberevaluationeligibilitycoverageundetectablefollow-upsuggesteverreceivingp = playstransmissionriskreductionpositivelymedicationadherenceoutcomesHoweverdatequantifiedparticularlyuseddatacohortadultsdescribeengagementretention20082009CopingHIV/AIDSCHATenrolled260clientsnewly492patientsestablishedtwolargecentersParticipantsagedoldercompletedannualclinicalassessmentstwice-annualin-personinterviews35yearsUsinglogisticregressionmodelsassessedsociodemographiccorrelatesmeasureantiretroviraltherapyRNAlevelsperiodMarriedindividualsearlierlikelydisclosedinfectionhighersignificantassociationobservedviralloadsMarginaleffectsestimates10disclose86%96%p = 0035compoundedCD4count62%80%0392055%75%029causalfindingsassistanceeffortscascade:evidence

Similar Articles

Cited By